Anebulo Pharmaceuticals, Inc. financial data

Symbol
ANEB on Nasdaq
Location
Jfl Capital Management, 1017 Rr 620 S, Suite 107, Lakeway, TX
State of incorporation
DE
Fiscal year end
June 30
Latest financial report
10-K - Q2 2024 - Sep 25, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 12.7 % +59.7%
Return On Equity -139 % -72.2%
Return On Assets -123 % -64.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 25.9M shares +1.17%
Common Stock, Shares, Outstanding 25.9M shares +1.17%
Entity Public Float 9.47M USD 0%
Common Stock, Value, Issued 25.9K USD +1.17%
Weighted Average Number of Shares Outstanding, Basic 25.8M shares +2.98%
Weighted Average Number of Shares Outstanding, Diluted 25.8M shares +2.98%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 3.55M USD -36.6%
General and Administrative Expense 4.76M USD -23%
Operating Income (Loss) -8.31M USD +29.5%
Nonoperating Income (Expense) 107K USD +109%
Net Income (Loss) Attributable to Parent -8.2M USD +30.1%
Earnings Per Share, Basic -0.32 USD/shares +31.9%
Earnings Per Share, Diluted -0.32 USD/shares +31.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.09M USD -72.5%
Assets, Current 3.51M USD -69.9%
Other Assets, Noncurrent 565K USD
Assets 4.07M USD -65.1%
Accounts Payable, Current 156K USD -70.7%
Accrued Liabilities, Current 104K USD -80.5%
Liabilities 261K USD -75.6%
Retained Earnings (Accumulated Deficit) -65.4M USD -14.3%
Stockholders' Equity Attributable to Parent 3.81M USD -64%
Liabilities and Equity 4.07M USD -65.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.73M USD -34.1%
Net Cash Provided by (Used in) Financing Activities 6.7M USD
Common Stock, Shares Authorized 50M shares +25%
Common Stock, Shares, Issued 25.9M shares +1.17%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.73M USD -158%
Deferred Tax Assets, Valuation Allowance 6.41M USD +36.8%
Deferred Tax Assets, Gross 6.41M USD +36.8%
Deferred Tax Assets, Operating Loss Carryforwards 3.74M USD +30.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 2M shares
Additional Paid in Capital 69.2M USD +2.08%
Preferred Stock, Shares Outstanding 0 shares
Interest Expense 59.7K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%